Aclarion Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

AclarionDer Gewinn des Unternehmens wird voraussichtlich um 6.5% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 136.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 46.6% pro Jahr wachsen.

Wichtige Informationen

-6.5%

Wachstumsrate der Gewinne

46.6%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	30.6%
Wachstumsrate der Einnahmen	136.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	24 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ACON - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	-7	N/A	-6	2
12/31/2024	-7	N/A	-7	2
9/30/2024	-6	-5	-5	N/A
6/30/2024	-6	-5	-5	N/A
3/31/2024	-6	-5	-5	N/A
12/31/2023	-5	-4	-4	N/A
9/30/2023	-5	-4	-4	N/A
6/30/2023	-5	-4	-4	N/A
3/31/2023	-7	-6	-6	N/A
12/31/2022	-7	-5	-5	N/A
9/30/2022	-8	-5	-5	N/A
6/30/2022	-9	-5	-4	N/A
3/31/2022	-6	-3	-2	N/A
12/31/2021	-6	-3	-2	N/A
9/30/2021	-5	-2	-2	N/A
6/30/2021	-5	-4	-3	N/A
3/31/2021	-5	-4	-3	N/A
12/31/2020	-5	-4	-4	N/A
12/31/2019	-5	-4	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ACON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ACON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ACON wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ACONDie Einnahmen des Unternehmens (136.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: ACONDie Einnahmen des Unternehmens (136.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ACON in 3 Jahren voraussichtlich hoch sein wird

Aclarion Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Aclarion Provides Update on Non-Compliance with Nasdaq’s Stockholders’ Equity Requirement and Nasdaq’s Bid Price Requirement

Aclarion, Inc. announced that it has received $1 million in funding

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Aclarion, Inc. has filed a Follow-on Equity Offering in the amount of $1.075 million.

Aclarion Launches Surgeon Partnership to Apply Nociscan's Ai Technology to Personal Injury and Workers Compensation Market

Aclarion Receives Non-Compliance Letter from Nasdaq Due to Non-Compliance with the Nasdaq Minimum Stockholders’ Equity Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.44 loss per share (vs US$2.39 loss in 1Q 2023)

Aclarion Receives Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Aclarion, Inc. has completed a Composite Units Offering in the amount of $3.0015 million.

Full year 2023 earnings released: US$8.82 loss per share (vs US$19.61 loss in FY 2022)

Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution

New major risk - Shareholder dilution

Aclarion, Inc. announced that it has received $0.25 million in funding

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.21 loss in 3Q 2022)

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Nasdaq Staff Determines to Delist the Aclarion Common Stock from Nasdaq, Unless the Company Timely Requests an Appeal of the Staff’s Determination to A Hearings Panel

Nasdaq Confirms Aclarion Regains Compliance with Rule 5250(c)(1) Regarding Filing of 10-Q Report

Aclarion Announces Update on Non-Compliance Notice from Nasdaq Regarding Late Filing of 10-Q Report

High number of new and inexperienced directors

Aclarion Receives Non-Compliance Notice From Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aclarion, Inc. Receives Nasdaq Notice Regarding Late Filing of 10-Q Report

Aclarion, Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.25 loss per share (vs US$6.58 loss in FY 2021)

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc. Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Aclarion, Inc.'s Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings released: US$1.35 loss per share (vs US$0.81 loss in 1Q 2021)

Director recently bought US$150k worth of stock